Patient Information Leaflet
Skilarence 30mg gastro-resistant tablets
dimethyl fumarate
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
What is Skilarence
Skilarence is a medication that contains the active ingredient dimethylfumarate. Dimethylfumarate acts on the cells of the immune system (the body's natural defenses), reducing the production of certain substances involved in the appearance of psoriasis through its action.
What is Skilarence used for
The Skilarence tablets are used to treat plaque psoriasis of moderate to severe severity in adults. Psoriasis is a disease that causes certain areas of the skin to thicken, inflame, or redden, often covered with white scales.
Generally, the response to Skilarence can be observed as early as week 3 and improves over time. Experience with related medications containing dimethylfumarate has shown that the beneficial effects of treatment last for at least 24 months.
Do not take Skilarence
-if you are allergic to dimethylfumarate or any of the other ingredients of this medicine (listed in section6)
-if you have severe stomach or intestinal problems
-if you have severe liver or kidney problems
-if you are pregnant or breastfeeding
Warnings and precautions
Consult your doctor or pharmacist before starting to take Skilarence.
Monitoring
Skilarence may cause blood, liver, or kidney problems. Blood and urine tests will be done before treatment and periodically during treatment. These tests are done to check that you do not have these complications and can continue to take this medicine. Depending on the results of these blood and urine tests, your doctor may decide to increase the dose of Skilarence as recommended (see section 3), maintain the dose, reduce the dose, or stop treatment completely.
Infections
White blood cells help the body fight infections. Skilarence may reduce the number of white blood cells. Talk to your doctor if you think you have contracted an infection. Symptoms include fever, pain, muscle aches, headache, loss of appetite, and general weakness. If you have a severe infection before starting treatment with Skilarence or during treatment, your doctor may recommend that you stop taking Skilarence until the infection is resolved.
Gastrointestinal disorders
Inform your doctor if you have or have had stomach or intestinal problems. Your doctor will advise you on precautions to take during treatment with Skilarence.
Children and adolescents
Children and adolescents under 18years of age should not take this medicine because it has not been studied in this age group.
Other medicines and Skilarence
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Especially, inform your doctor if you are taking the following:
If you have severe diarrhea due to the use of Skilarence, other medicines may not work as well as they should. If you have severe diarrhea, consult your doctor. If you are taking a contraceptive (the pill), this is especially important as the effect may be reduced and you may need to use other contraceptive methods to prevent pregnancy. See the instructions in the package insert of the contraceptive you are taking.
If you need to be vaccinated, consult your doctor. Certain types of vaccines (attenuated vaccines) may cause an infection if used during treatment with Skilarence. Your doctor may advise you on what is best.
Skilarence and alcohol
Do not consume strong alcoholic beverages (more than 50ml of spirits containing more than 30% alcohol by volume) during treatment with Skilarence, as alcohol may interact with this medicine. This interaction between alcohol and the medicine may cause stomach and intestinal problems.
Pregnancy and breastfeeding
Do not take Skilarence if you are pregnant or intend to become pregnant, as Skilarence may cause harm to the baby. Use effective contraceptive methods to avoid becoming pregnant during treatment with Skilarence (see also “Other medicines and Skilarence” above).
Consult your doctor if you experience stomach or intestinal problems that may reduce the effectiveness of oral contraceptives, who will advise you on other contraceptive methods.
Do not breastfeed during treatment with Skilarence.
Driving and operating machinery
The influence of Skilarence on the ability to drive and operate machinery is small. You may feel dizzy or tired after taking Skilarence. If you are affected, be careful when driving or operating machinery.
Skilarence contains lactose
If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
Skilarence contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; that is, it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Dose
Your doctor will start treatment with a low dose of Skilarence using 30 mg tablets. This helps your body adapt to the medication and reduces the risk of side effects, such as stomach and intestinal problems. The dose will be increased every week by 30 mg as indicated in the table below. Once you reach the Skilarence dose of 120 mg per day, usually from week 4, you can switch to 120 mg tablets for convenience. When changing from 30 mg to 120 mg, make sure the tablet and dose you are taking are correct.
Treatment week | Tablet presentation | Number of tablets to be taken during the day | Number of tablets per day | Total daily dose | ||
Breakfast | Lunch | Dinner | ||||
1 | 30 mg | ‑ | ‑ | 1 | 1 | 30 mg |
2 | 30 mg | 1 | ‑ | 1 | 2 | 60 mg |
3 | 30 mg | 1 | 1 | 1 | 3 | 90 mg |
4 | 120 mg | ‑ | ‑ | 1 | 1 | 120 mg |
5 | 120 mg | 1 | ‑ | 1 | 2 | 240 mg |
6 | 120 mg | 1 | 1 | 1 | 3 | 360 mg |
7 | 120 mg | 1 | 1 | 2 | 4 | 480 mg |
8 | 120 mg | 2 | 1 | 2 | 5 | 600 mg |
9+ | 120 mg | 2 | 2 | 2 | 6 | 720 mg |
Your doctor will check how your condition is improving after starting to take Skilarence and also if you experience any side effects. If you experience severe side effects after increasing the dose, your doctor may recommend that you temporarily return to the previous dose. If the side effects are not very bothersome, the dose will be increased until your condition is well controlled.It is possible that you will not need the maximum dose of 720 mg per day as indicated in the table above. Once your condition has improved enough, your doctor will study how to gradually reduce the daily dose of Skilarence to the dose you need to maintain the improvement.
Administration form
Skilarence tablets should be swallowed whole with a liquid. Take the tablet(s) during a meal or immediately after it. Do not crush, break, dissolve, or chew the tablets, as they have a special coating that helps prevent stomach irritation.
If you take more Skilarence than you should
If you think you have taken too many Skilarence tablets, contact your doctor or pharmacist.
If you forgot to take Skilarence
Do not take a double dose to compensate for the missed doses. Take the next dose at the usual time and continue taking the medication exactly as described in this leaflet or exactly as agreed with your doctor. In case of doubt, consult your doctor or pharmacist.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Some of these side effects, such as facial or body redness, diarrhea, stomach problems, and nausea, usually improve as treatment continues.
The most serious side effects that can occur with Skilarence are allergic reactions or hypersensitivity, kidney insufficiency or a kidney disease called Fanconi syndrome, or a severe brain infection called progressive multifocal leukoencephalopathy (PML). The frequency of these events is unknown. For more information on symptoms, see the information included below.
Allergic reactions or hypersensitivity
Allergic reactions or hypersensitivity are rare but can be very serious. Facial or body redness (erythema) is a very common side effect that can affect more than 1 in 10 people. However, if you experience redness and any of the following symptoms:
Stop taking Skilarence and call your doctor immediately.
Brain infection called PML
Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection that can lead to significant disability or death. If you notice the onset or worsening of weakness on one side of the body; clumsiness; visual, thought, or memory disturbances; confusion; or changes in personality that last for several days, stop taking Skilarence and speak with your doctor immediately.
Fanconi syndrome
Fanconi syndrome is a rare but serious kidney disorder that can occur when taking Skilarence. If you are urinating more (or more frequently), have increased thirst and are drinking more than usual, your muscles seem weaker, you break a bone, or you simply have pain and discomfort, speak with your doctor as soon as possible so they can perform additional investigations.
Consult your doctor if you experience any of the following side effects.
Very common(can affect more than 1 in 10 people):
Common(can affect up to 1 in 10 people):
Uncommon(can affect up to 1 in 100 people):
Rare(can affect up to 1 in 1,000 people):
Very rare(can affect up to 1 in 10,000 people):
Unknown(cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and the blister after "EXP". The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the packaging and the medication that you no longer need. In this way, you will help protect the environment.
Skilarence 30 Compositionmg
Appearance of the product and contents of the package
Skilarence 30mg is a white and round tablet, with an approximate diameter of 6.8mm.
Skilarence 30mg is available in packages of: 42, 70 and 210gastro-resistant tablets.
Only some package sizes may be marketed. The tablets are packaged in aluminum and PVC/PVDC blisters.
Marketing Authorization Holder
Almirall, S.A.
Ronda General Mitre, 151
08022 Barcelona
Spain
Phone +34 93 291 30 00
Responsible for manufacturing
Industrias Farmacéuticas Almirall, S.A.
Ctra. de Martorell 41-61
08740 Sant Andreu de la Barca, Barcelona
Spain
For more information about this medication, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien/ Luxembourg/Luxemburg Almirall N.V.Tél/Tel: +32 (0)2 771 86 37 |
EGIS Pharmaceuticals PLC, Te?. +359 2 987 60 40 |
Ceská republika EGIS Praha, spol. s.r.o.,Tel: +420 227 129 111 |
Danmark/ Norge/ Sverige Almirall ApS Tlf./Tel: +45 70 25 75 75 |
Deutschland Almirall Hermal GmbH, Tel: +49 (0)40 72704-0 |
Eesti /España/ Hrvatska/Kúπρος/Latvija/Lietuva/ Malta/ România/ Slovenija Almirall, S.A.,Te?./Tel/Τηλ: +34 93 291 30 00 |
Ελλáδα Galenica A.E,Τηλ: +30 21052 81 700 |
Francia Almirall SAS Tél: +33(0)1 46 46 19 20 |
Ireland Almirall, S.A. Tel: +353 1800 849322 |
Ísland Vistorhf. Sími: +354 535 70 00 |
Italia Almirall SpA Tel: +39 02 346181 |
Magyarország Egis Gyógyszergyár Zrt., Tel.: +36 1 803 5555 |
Nederland Almirall B.V. Tel: +31 (0) 30 711 15 10 |
Österreich Almirall GmbH Tel: +43 (0)1/595 39 60 |
Polska EGIS Polska Sp. z o.o., Tel.: +48 417 92 00 |
Portugal Almirall- Productos Farmacêuticos, Lda.Tel: +351 21 415 57 50 |
România Egis Pharmaceuticals PLC, Tel: +40 21412 0017 |
Slovenská republika EGISSLOVAKIAspols.r.o.Tel: +421 2 32409422 |
Suomi/Finland Orion Pharma Puh/Tel: +358 10 4261 |
Last review date of this leaflet.
Other sources of information
More detailed information about this medication is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.